Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7292-7303

  Maccalli, Cristina ^a,c,d   Di Cristanziano, Veronica ^a   Fodale, Valentina ^a   Corsi, Domenico ^a   D'Agostino, Giuseppina ^a   Petrangeli, Valentina ^a   Laurenti, Luca ^b   Guida, Sofia ^b   Mazzocchi, Arabella ^d   Arienti, Flavio ^d   Perrone, Maria P ^b   Castelli, Chiara ^d   Rivoltini, Licia ^d   Zagonel, Vittorina ^a   Tartaglia, Marco ^a   Parmiani, Giorgio ^c,d   Belardelli, Filippo ^a  

^a SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLON ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG; COLORECTAL TUMOR ASSOCIATED ANTIGEN, HUMAN; COLORECTAL TUMOR-ASSOCIATED ANTIGEN, HUMAN; GAMMA INTERFERON; HLA A ANTIGEN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; ANTIGEN PRESENTATION; BIOSYNTHESIS; COLORECTAL TUMOR; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; HLA-A ANTIGENS; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION;

EID: 58149337453     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0832     Document Type: Article

References (49)

1. Chung KY, Saltz LB. Antibody-based therapies for colorectal cancer. Oncologist 2005;10:701-9.
2. Kelly HR, Goldberg M. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:4553-60.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
4. Boon T, van Baren N. Immunosurveillance against cancer and immunotherapy - synergy or antagonism? N Engl J Med 2003;348:252-4.
5. Dunn GP, Old JL, Screiber RD. The three e's of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
6. Mihm M, Clemente C, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996;74:43-7.
7. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
8. Schumacher H, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2002;61:3932-6.
9. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
10. Parmiani G. Tumor-infiltrating T cells - friend or foe of neoplastic cells? N Engl J Med 2005;353:2640-1.
11. Rapponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997;183:318-24.
12. + immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis 2002;17:25-9.
13. Pagès F, Bergen A, Camus M, et al. Effector memory T cells, early metastasis and survival in colorectal cancer. N Engl J Med 2005;353:2654-66.
14. Galon J, Fridman W-H, Pagès F. The adaptive immunologic microenvironment in colorectal cancer. A novel perspective. Cancer Res 2007;67:1883-6.
15. Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003;46:33-57.
16. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells. March 2004, up-date. Cancer Immunol Immunother 2005;54:187-207.
17. Parmiani G, Pilla L, Castelli C and Rivoltini L. Vaccination of patients with solid tumours. Ann Oncol 2003;14:817-24.
18. Belardelli F, Ferrantini M, Parmiani G, Schlom J, Garaci E. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res 2004;64:6827-30.
19. Mocellin S, Rossi CR, Lise M, Marincola FM. Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol Immunother 2002;51:583-95.
20. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004;53:275-306.
21. Nagorsen D, Thiel E. Clinical and immunological responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 2006;12:3064-9.
22. Pittet MJ, Valmori D, Dunbar PR, et al. High frequencies of naïve Melan-A/Mart-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999;190:705-15.
23. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-85.
24. Valmori D, Scheibenbogen C, Dutoit V, et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 2002;62:1743-50.
25. Rodolfo M, Luksch R, Stockert E, et al. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res 2003;63:6948-55.
26. Nagorsen D, Keilholz U, Rivoltini L, et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, HER-2/neu, and carcinoembryogenic antigen in patients with colorectal cancer. Cancer Res 2000;60:4850-4.
27. Nagorsen D, Scheibenbogen C, Letsch A, et al. T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. J Transl Med 2005;3:3-38.
28. Anichini A, Vegetti C, Mortarini R. The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 2004;53:855-64.
29. Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res 2003;63:6735-43.
30. Katoh H, Harada A, Mori K, Negishi M. Socius is a novel Rnd GTPase-interacting protein involved in disassembly of actin stress fibers. Mol Cell Biol 2002;22:2952-64.
31. 12-induced RhoA activation. Biochem Biophys Res Commun 2005;337:615-620.
32. + T cell response. J Immunol 2003;170:5195-202.
33. Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, Rosenberg SA. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol 2002;169:6036-47.
34. Harashima N, Tanaka K, Sasatomi T, et al. Recognition of the Lck tyrosine kinase as a tumor antigen and cytotoxic T lymphocytes of cancer patients with distant metastases. Eur J Immunol 2003;31:323-32.
35. Parmiani G, Sensi M L, Castelli C, Rivoltini L, Anichini A. T-cell response to unique and shared antigens and vaccination of cancer patients. Cancer Immunol 2002;2:6-15.
36. + T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 2003;63:2535-45.
37. Pupa S M, Menard S, Andreola S, Colnaghi MI. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 1993;53:5864-6.
38. Fishman P, Merinmski O, Baharav E, Shoenfeld Y. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer (Phila) 1997;79:1461-4.
39. Mosolits S, Harmenberg U, Ruden U, et al. Autoantibodies against the tumor-associate antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol Immunother 1999;47:315-20.
40. Jager E, Stockert E, Zidianakis Z, et al. Humoral immune response of cancer patients against "cancer-testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999;84:506-10.
41. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
42. Yokoyama WM. Catch us if you can. Nature 2002;419:679-80.
43. Oppenheim DE, Roberts SJ, Clarke SL, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2004;6:928-37.
44. Shafer-Weaver K, Rosenberg S, Strobl S, Alvord SG, Baseler W, Anatoli MM. Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials. J Immunother 2006;29:328-35.
45. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005;17:326-32.
46. Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol 2003;3:189-98.
47. + suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 2003;26:85-93.
48. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004;20:107-18.
49. Casey AC, Fang Dong H, Howard ZOM, Oppenheim JJ, Hanisch F-G, Finn OJ. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 2005;175:1628-35.